Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego.
The data include eight abstracts for Taltz, featuring two oral presentations highlighting patient-reported outcomes from a Phase 3 clinical trial evaluating Taltz for the treatment of moderate-to-severe genital psoriasis, as well as findings from the Corrona Psoriasis Registry on Taltz patient clinical characteristics and treatment history. Two abstracts evaluating the efficacy and safety of Taltz for the treatment of active psoriatic arthritis will also be presented.
Additionally, Lilly will present Phase 2 efficacy, safety and patient-reported outcomes data for mirikizumab in moderate-to-severe plaque psoriasis. Lilly will also present a late-breaker abstract on patient-reported outcomes data from a Phase 2 study evaluating baricitinib for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners in the development of baricitinib). One abstract from the Closer Together Survey, a survey where nearly 2,000 people with moderate-to-severe psoriasis from 17 countries cross Europe and Canada shared how psoriasis impacts their quality of life and their overall satisfaction with treatment, will also be presented. An additional three abstracts will detail results from studies investigating immune-mediated diseases.
"The data being presented at AAD demonstrates our commitment to developing treatment advancements to help patients with severe diseases such as psoriasis and atopic dermatitis find relief," said Lotus Mallbris, M.D., vice president, immunology platform team leader, Lilly Bio-Medicines. "We are pleased to share data underscoring the potential of our immunology portfolio."